Here is an article referencing the results of the stage II trials, and it reports that the drug was well tolerated- 96% of those who enrolled completed the trial and here is a quote:
<br><div class="FTQUOTE"><begin quote>Safety results from the study showed that ataluren was generally well tolerated. Most adverse events were mild or moderate and compliance with study drug was greater than 96% for all patients.</end quote>
<br>Phase III has been an ongoing 48wk trial, and results will be reported in the first half of 2012. This is potentially a very exciting drug- not only could it help the 10%+/- of those with CF that have nonsense mutations, but similar percentages of those with a few other diseases could be benefited as well due to nonsense mutations causing their conditions.<br><br>eta> sorry, forgot to post the link!<br><a target="" title="" href="http://www.drugs.com/clinical_trials/ataluren-phase-2-data-nonsense-mutation-cystic-fibrosis-published-european-respiratory-journal-12073.html">http://www.drugs.com/clinical_trials/ataluren-phase-2-data-nonsense-mutation-cystic-fibrosis-published-european-respiratory-journal-12073.html</a><br>